Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 4
Submit an article Journal homepage
34
Views
4
CrossRef citations to date
0
Altmetric
Review

Emerging targeted treatments for malignant glioma

Paul J Mulholland Imperial College of Medicine, Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK. [email protected]
,
Christina Thirlwell Imperial College of Medicine, Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK. [email protected]
,
Cathryn S Brock Imperial College of Medicine, Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK. [email protected]
&
Edward S Newlands Imperial College of Medicine, Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK. [email protected]
Pages 845-854 | Published online: 31 Oct 2005

Bibliography

  • KLEIHUES P, CAVANEE WK: World Health Organization classification of tumours of the nervous system. Lyon, France (2000).
  • STEWART LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet (2002) 359(9311):1011–1018.
  • CBTRUS: Statistical Report. Primary Brain Tumors in the United States, 2004-2005.
  • YUNG WK, PRADOS MD, YAYA-TUR R et al.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. OncoL (1999) 17(9):2762–2771.
  • YUNG WK: Temozolomide in malignant gliomas. Semin. OncoL (2000) 27(3 Suppl. 6):27–34.
  • GILBERT MR, FRIEDMAN HS, KUTTESCH JF et al.: A Phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncoL (2002) 4(4):261–267.
  • DINNES J, CAVE C, HUANG S, MILNE R: A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br. J. Cancer (2002) 86(4):501–505.
  • ANTONADOU D, PARASKEVAIDIS M, SARRIS G et al.: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. OncoL (2002) 20(17):3644–3650.
  • STUPP R, DIETRICH PY, OSTERMANN KRALJEVIC S et al.: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. j Clin. OncoL (2002) 20(5):1375–1382.
  • STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N EngL J. Med. (2005) 352(10987–996.
  • ATHANASSIOU H, SYNODINOU M, MARAGOUDAKIS E et al.: Randomized Phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J. Clin. OncoL (2005) 23(10):2372–2377.
  • BREDEL M, ZENTNER J: Brain-tumour drug resistance: the bare essentials. Lancet OncoL (2002) 3(7):397–406.
  • BREDEL M, BREDEL C, SIKIC BI: Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours? Lancet OncoL (2004) 5(2):89–100.
  • LANG FF, BRUNER JM, FULLER GN et al.: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. OncoL (2003) 21(13):2508–2518.
  • LI H, ALONSO-VANEGAS M, COLICOS MA et al.: Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin. Cancer Res. (1999) 5(3):637–642.
  • LOHRUM MA, LUDWIG RL, KUBBUTAT MH, HANLON M, VOUSDEN KH: Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. (2003) 3(6):577–587.
  • VASSILEV LT, VU BT, GRAVES B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303(5659):844–848.
  • PRASAD G, WANG H, AGRAWAL S, ZHANG R: Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res. (2002) 22(1A):107–116.
  • ROBINSON DR, WU YM, LIN SF: The protein tyrosine kinase family of the human genome. Oncogene (2000) 19(49):5548–5557.
  • SHINOJIMA N, TADA K, SHIRAISHI S et al.: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. (2003) 63(20):6962–6970.
  • FUJIWARA K, KIURA K, UEOKA H, TABATA M, HAMASAKI S, TANIMOTO M: Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer (2003) 40(1):73–76.
  • RICH JN, REARDON DA, PEERY T et al.: Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. OncoL (2004) 22(1):133–142.
  • HALATSCH ME, GEHRKE EE, VOUGIOUKAS VI et al.: Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. Neurosurg (2004) 100(3):523–533.
  • GOUDAR RK, SHI Q, HJELMELAND MD et al.: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. MoL Cancer Ther. (2005) 4(1):101–112.
  • DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N EngL J. Med. (2001) 344(14):1038–1042.
  • DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N EngL J. Med. (2001) 344(14):1031–1037.
  • KILIC T, ALBERTA JA, ZDUNEK PR et al.: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. (2000) 60(105143–5150.
  • FRIEDMAN HS, QUINN JA, RICH JN et al.: Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results. J. Clin. OncoL Proc. Am. Soc. Clin. OncoL (2005) 24:1515a.
  • CHAUDHRY IH, O'DONOVAN DG, BRENCHLEY PE, REID H, ROBERTS IS: Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology (2001) 39(4):409–415.
  • CHENG SY, HUANG HJ, NAGANE M et al.: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA (1996) 93(16):8502–8507.
  • STEFANIK DF, FELLOWS WK, RIZKALLA LR et al.: Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J. Neuro-oncoL (2001) 55(2):91–100.
  • WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60(8):2178–2189.
  • REARDON DA, FRIEDMAN HS, YUNG WK et al.: A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastome multiforme (GBM). J. Clin. OncoL Proc. Am. Soc. Clin. OncoL (2004) 22:1513a.
  • GOLDBRUNNER RH, BENDSZUS M, WOOD J, KIDERLEN M, SASAKI M, TONN JC: PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery (2004) 55(2):426–432; discussion 432.
  • SAKATA K, KATO S, FOX JC, SHIGEMORI M, MORIMATSU M: Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway. NeuropathoL Exp. NeuroL (2002) 61(11):975–983.
  • HOWE LR, LEE VERS SJ, GOMEZ N, NAKIELNY S, COHEN P, MARSHALL CJ: Activation of the MAP kinase pathway by the protein kinase raf. Cell (1992) 71(2):335–342.
  • XIA W, MULLIN RJ, KEITH BR et al.: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 21(41):6255–6263.
  • SPECTOR NL, XIA W, BURRIS H 3rd et al.: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. OncoL (2005) 23(11):2502–2512.
  • ESHLEMAN JS, CARLSON BL, MLADEK AC, KASTNER BD, SHIDE KL, SARKARIA JN: Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. (2002) 62(24):7291–7297.
  • RICH JN, REARDON DA, QUINN JA et al.: A phase I trial of gefitinib (ZD1839) plus rapamycin for patients with recurrent malignant glioma. j Clin. OncoL Proc. Am. Soc. Clin. OncoL (2005) 23:1565a.
  • DAS A. BADRUDDOJA M, TRYCIECKY D, YU J, BLACK K: Phase I study of gefitinib and rapamycin in patients with recurrent or progressive glioblastoma (GBM). j Clin. OncoL Proc. Am. Soc. Clin. OncoL (2005) 23:1572a.
  • CHANG SM, KUHN J, WEN P et al.: Phase 1/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest. New Drugs (2004) 22(4):427–435.
  • BEUVINK I, BOULAY A, FUMAGALLI S et al.: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell (2005) 120(6):747–759.
  • MANNE V, ROBERTS D, TOBIN A et al.: Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc. Nail. Acad. Sci. USA (1990) 87(19):7541–7545.
  • GLASS TL, LIU TJ, YUNG WK: Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor 5CH66336. Neuro-oncol. (2000) 2(3):151–158.
  • FELDKAMP MM, LALA P, LAU N, RONCARI L, GUHA A: Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery (1999) 45(6):1442–1453.
  • WANG E, CASCIANO CN, CLEMENT RP, JOHNSON WW: The farnesyl protein transferase inhibitor 5CH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res. (2001) 61(20):7525–7529.
  • DELMAS C, END D, ROCHADC P, FAVRE G, TOULAS C, COHEN-JONATHAN E: The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin. Cancer Res. (2003) 9(16 Pt 1):6062–6068.
  • STRUMBERG D, RICHLY H, HILGER RA et al.: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. OncoL (2005) 23(5):965–972.
  • NAGANUMA H, SATOH E, ASAHARAT et al.: Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3betal integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells. J. Neuro-oncoL (2004) 70(3):309–317.
  • ESKENS FA, DUMEZ H, HOEKSTRA R, et al.: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins av133 and av135 in patients with advanced solid tumours. Eur. j Cancer (2003) 39(7):917–926.
  • MAHER EA, FURNARI FB, BACHOO RM et al.: Malignant glioma: genetics and biology of a grave matter. Genes Dev. (2001) 15(11):1311–1333.
  • DAVIES DC: Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J. Anat. (2002) 200(6):639–646.
  • DEMPSEY MF, CONDON BR, HADLEY DM: Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am. J. NeuroradioL (2005) 26(4):770–776.
  • SCHATZKIN A, GAIL M: The promise and peril of surrogate end points in cancer research. Nat. Rev. Cancer (2002) 2(1):19–27.

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.